Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation (OTCQB: BRCNF; TSX: BU) regularly issues news updates that focus on its progress in plant-based protein innovation and commercialization. As a company that describes itself as a global technology leader in high-performance plant-based proteins for the food and beverage industry, its announcements often highlight developments in product performance, customer adoption, and financing activities.
News items from Burcon frequently cover milestones in commercial production and sales of its branded ingredients, such as Puratein® C canola protein, FavaPro™ fava protein, Peazazz® C pea protein, and Solatein™ sunflower protein. The company reports on first commercial production runs, initial commercial sales, and commercial sales orders for its next generation proteins, as well as the progression of customers from evaluation to purchase orders across its pea, canola, and fava platforms.
Burcon’s releases also include updates on scientific and technical validation of its ingredients. For example, the company has reported on a University of Guelph study in which its pea and sunflower proteins were found to outperform a competitor’s pea protein in a plant-based cheese application, with commentary on melt, stretch, and sensory attributes.
In addition, the company’s news flow features financial and corporate developments, including fiscal results, revenue trends from protein sales and contract manufacturing services, non-brokered private placements of convertible debentures, short-term loan agreements, and insider participation in financings. Governance-related announcements, such as board appointments and shareholder meeting results, are also part of its disclosures.
Investors and industry observers who follow Burcon’s news can track how the company describes its commercialization progress, customer pipeline, manufacturing partnerships, and capital structure as it advances its plant-based protein business.
Burcon NutraScience Corporation (BRCNF), a leader in plant-based protein technology, has been invited to present at the 2025 Canadian Climate Investor Conference (CCIC) on June 11, 2025 in Toronto. CEO Kip Underwood will showcase Burcon's sustainability initiatives and growth potential, particularly highlighting their upcoming commercial production launch. The CCIC, hosted by TSX and TSXV, aims to connect clean technology companies with climate-conscious investors to accelerate sustainable development in Canada.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) has successfully completed the installation and commissioning of its proprietary protein processing equipment at its Galesburg, Illinois facility. The integration was accomplished in just 10 days through collaboration with RE ProMan
The Galesburg facility, a certified commercial food processing site, has been equipped with new piping, electrical systems, and proprietary equipment aligned with Burcon's core protein technology platform. This development positions the company to:
- Scale up production
- Optimize operations
- Advance commercial partnerships
- Launch its complete portfolio of protein products
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) announces that its alliance partner, RE ProMan, , has completed the acquisition of a protein production facility in Galesburg, Illinois. The facility was chosen for its strategic location near agricultural growers and key transportation routes, as well as its existing processing capabilities that align with Burcon's protein technology platform.
The company plans to integrate its proprietary technologies into the facility and expects to begin commercial-scale production of protein products during the first half of 2025. This acquisition represents Burcon's first operational control of a commercial facility, positioning the company to deliver sustainable plant-based protein solutions to meet market demand.
Burcon NutraScience has successfully completed a rights offering, raising $9.43 million through the issuance of 110,986,126 common shares at $0.085 per share. The offering received strong support from strategic investors, including management and board members.
A total of 77,198,140 shares were issued under basic subscription rights, with 19,061,806 shares going to insiders and 58,136,334 to other investors. Additional subscription privileges resulted in 33,787,986 shares being issued. Following the offering, Burcon has 253,761,444 common shares outstanding.
The Insider Group now owns 30.64% of outstanding shares. The proceeds will primarily fund Burcon's obligations under a recently announced Manufacturing Agreement with RE ProMan, , and support the commercialization and scaling of protein products.
Burcon NutraScience (TSX: BU) (OTCQB: BRCNF) reported its fiscal 2025 Q3 results, marking a transformative period with several key developments. The company formed an alliance with ProMan to acquire and operate a protein production facility, which is in final due diligence phase. Burcon generated $62,000 in revenues and reported a net loss of $1.8 million ($0.01 per share), compared to $2.0 million loss in the same period last year.
The company successfully closed a rights offering raising $9.43 million, exceeding their $7 million target for production, marketing, and sales initiatives. Burcon launched new products including next-generation Peazazz® pea protein, Puratein® canola protein, and Solatein™ sunflower protein isolate. The company has over 100 customers evaluating their proteins and expects to begin commercial scale production in the first half of 2025.
Burcon NutraScience has successfully completed its rights offering, raising approximately $9.43 million through the issuance of 110,986,126 Common shares at $0.085 per share. The Rights Offering, which expired on February 12, 2025, exceeded the company's target of $7 million needed to execute its production plan and achieve positive cash flow by calendar 2026.
The company, a global technology leader in plant-based protein development, is currently working with its transfer agent to calculate the amounts exercised under the basic subscription privilege and additional subscription privilege. Further details, including information required by National Instrument 45-106, will be provided once available.
Burcon has registered the offer and sale of shares on a Form F-7 registration statement under the U.S. Securities Act of 1933. The company has also scheduled a virtual investor presentation for February 18, 2025, at 5:00 p.m. Eastern time.
FAQ
What is the current stock price of Burcon Nutrascience (BRCNF)?
What is the market cap of Burcon Nutrascience (BRCNF)?
